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Agmatine Attenuates Brain Edema and Apoptotic Cell Death 
after Traumatic Brain Injury
Traumatic brain injury (TBI) is associated with poor neurological outcome, including 
necrosis and brain edema. In this study, we investigated whether agmatine treatment 
reduces edema and apoptotic cell death after TBI. TBI was produced by cold injury to the 
cerebral primary motor cortex of rats. Agmatine was administered 30 min after injury and 
once daily until the end of the experiment. Animals were sacrificed for analysis at 1, 2, or 
7 days after the injury. Various neurological analyses were performed to investigate 
disruption of the blood-brain barrier (BBB) and neurological dysfunction after TBI. To 
examine the extent of brain edema after TBI, the expression of aquaporins (AQPs), 
phosphorylation of mitogen-activated protein kinases (MAPKs), and nuclear translocation 
of nuclear factor-κB (NF-κB) were investigated. Our findings demonstrated that agmatine 
treatment significantly reduces brain edema after TBI by suppressing the expression of 
AQP1, 4, and 9. In addition, agmatine treatment significantly reduced apoptotic cell death 
by suppressing the phosphorylation of MAPKs and by increasing the nuclear translocation 
of NF-κB after TBI. These results suggest that agmatine treatment may have therapeutic 
potential for brain edema and neural cell death in various central nervous system diseases.
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INTRODUCTION
Traumatic brain injury (TBI) is a complex process that includes 
primary, secondary or additional injury, and regeneration (1). 
Secondary injury mechanisms include complex biochemical 
and physiological processes that are initiated by the primary in-
sult and manifest over a period of hours to days (2, 3). The ini-
tial disturbances caused by TBI lead to apoptotic cell death and 
brain edema, but the molecular mechanisms underlying these 
processes are unclear. Brain edema is a pathological condition 
of increased water content resulting from various coexisting 
brain injuries, including ischemia, trauma, tumors, and infec-
tion. Aquaporins (AQPs) are transmembrane proteins that se-
lectively allow the passage of water through the plasma mem-
brane of fluid-transporting cell types throughout the body. Re-
cent studies have suggested activation of MAPKs as a molecular 
mechanism for brain edema and neural cell death in both in vi-
tro and in vivo traumatic injury models (4-8). MAPKs also par-
ticipate in osmotic shock-induced stimulation of AQP4 and 9 in 
rat cortical astrocytes (8, 9). 
 Moreover, nuclear factor-κB (NF-κB) regulates transcription-
al activity in the nucleus and is involved in various cellular ac-
tivities. NF-κB triggers several anti-apoptotic genes that inter-
rupt the apoptotic cascade at multiple levels (10, 11). Therefore, 
NF-κB nuclear translocation plays a pivotal role in the transcrip-
tional regulation of cell survival and death. Agmatine is an en-
dogenous polyamine formed by the decarboxylation of L-argi-
nine by arginine decarboxylase (ADC). Agmatine is an endoge-
nous clonidine-displacing substance, an agonist for both α2-
adrenergic and imidazoline receptors, and selectively blocks N-
methyl-D-aspartate (NMDA) receptors (12-14). Agmatine treat-
ment was reported to have various biological actions and neu-
roprotective effects on multiple central nervous system (CNS) 
diseases (12, 15-25). We have previously reported that agmatine 
attenuates brain edema by limiting blood-brain barrier (BBB) 
disruption and blocking the accumulation of brain water con-
tent by lessening AQP1 expression after cerebral ischemia (22). 
In addition, agmatine facilitated the activation and nuclear trans-
location of NF-κB in astrocytes following oxygen/glucose depri-
vation (21). All of these cellular mechanisms may contribute to 
the neuroprotective effects of agmatine. 
 Based on these observations, we hypothesized that agmatine 
may have neuroprotective effects on brain edema and apoptot-
ic cell death by suppressing AQP expression, MAPK phosphor-
ylation, and promoting the translocation of NF-κB into the nu-
cleus after TBI.
 
ORIGINAL ARTICLE
Neuroscience
Kim JY, et al. • Agmatine Attenuates Brain Edema after Traumatic Brain Injury
944  http://jkms.org http://dx.doi.org/10.3346/jkms.2015.30.7.943
MATERIALS AND METHODS 
TBI model 
Eight-week-old male Sprague-Dawley rats (290 ± 20 g, SAMTA-
KO, Osan, Korea) were subjected to TBI. Experimental animals 
were anesthetized with a mixture of Zoletil 50 (24 mg/kg) and 
Rompun (16 mg/kg). Anesthetized rats were placed on a con-
ventional stereotactic frame, and a craniotomy was performed 
over the right forelimb motor cortex. Craniotomy was carried 
out by drilling +2 mm anterior and -2 mm posterior from Breg-
ma and +1-5 mm lateral from the midline (Fig. 1). The bone was 
thinned with a grinder bit over the forelimb motor cortex, and 
the dura mater was left intact to prevent bleeding. TBI was in-
duced by placement of a metal probe (3 mm in diameter) cooled 
by liquid nitrogen onto the right forelimb motor cortex. The mo-
tor cortex was exposed to the cooled probe five times for 30 sec 
of injury and 30 sec of rest (26). The physiological parameters of 
the animals were monitored and maintained before injury. All 
of the experimental animals were maintained under a 12-hr 
light/dark cycle and were sacrificed for analysis 1, 2, or 7 days 
after injury.
Agmatine administration
Agmatine (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
normal saline and injected intraperitoneally (100 mg/kg) 30 
min after TBI and once daily until the end of the experiment. 
The daily dosage and timing of agmatine administration were 
determined from previous experiments (22, 25). Experimental 
control animals received normal saline in equivalent volumes 
(Fig. 1). 
Determination of BBB disruption 
Animals were injected intravenously with Evans Blue solution 
(2% in saline; 4 mg/kg; Sigma-Aldrich) at the onset of reperfu-
sion and incubated for 60 min under anesthesia. Animals were 
perfused transcardially with normal saline. Coronally dissected 
2 mm thick brain sections were analyzed using a computer-as-
sisted image analysis system (Image J 1.36b; NIH, Rockville Pike, 
MD, USA). 
Measurement of swelling volume and brain water content
Experimental animals were sacrificed to analyze maximal brain 
edema 1 or 2 days after TBI (18, 21, 22). Coronally dissected 2 
mm thick brain sections were examined for the swelling vol-
ume and brain water content. The swelling volume (%) was cal-
culated as follows: (volume of ipsilateral hemisphere/volume 
of contralateral hemisphere) × 100. 
 To determine the brain water content, whole brains were sep-
arated sagittally and weighed to obtain the wet weights (WWs) 
and dry weights (DWs) of each hemisphere before and after dry-
ing at 110°C for 24 hr, and the water content (%) was calculated 
as follows: (WWs-DWs)/WWs × 100 (27).
Fig. 1. Dorsal and coronal views of the rat skull and experimental scheme. Experimental animals were anesthetized and placed on the stereotactic frame. Craniotomy was per-
formed above the right forelimb motor cortex at +2 mm anterior and -2 mm posterior from Bregma and +1-5 mm lateral from the midline. The representative figure is from 
"The Rat Brain in Stereotaxic Coordinates,” fourth edition, George Paxinos & Charles Watson, Academic Press 1998.
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Measurement of apoptosis by terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining
TUNEL staining was performed following the manufacturer’s 
instructions (In Situ Cell Death Detection Kit; Roche Diagnos-
tics, Indianapolis, IN, USA). Briefly, brain sections were depar-
affinized, rehydrated, and washed with phosphate buffered sa-
line (PBS). Proteinase K was then added, and sections were in-
cubated for 30 min at 37°C. Sections were washed twice with 
PBS, stained with the TUNEL reaction mixture for 60 min at 37°C, 
and washed twice with PBS. DNA fragmentation was observed 
under a fluorescence microscope (LSM 510 META; Carl Zeiss, 
Oberkochen, Germany).
Behavior tests
To examine the change in motor function, all of the animals were 
tested after TBI using the rotarod and limb placement tests. An-
imals were assessed on an accelerating rat-sized rotarod (ENV-
577; Med Associates, Inc., St. Albans, VT, USA). The rod speed 
was gradually accelerated from 4 to 40 rpm. The limb placement 
test has been described elsewhere (28). Briefly, forelimb and 
hindlimb placement was evaluated under seven different con-
ditions. A total of 0 points indicated maximal neurological defi-
cit, and 24 points indicated normal performance. Animals were 
tested five times on each testing day with a minimum of 5 min 
of rest in the home cage between trials.
Observation of protein expression levels by 
immunohistochemical staining 
Brains were fixed with a 4% paraformaldehyde solution, em-
bedded in paraffin, and sectioned (10 µm). Sections were im-
munostained with primary antibody to either p-ERK (#9101), 
p-JNK (#9255), or p-P38 (#4631; all from Cell Signaling, Dan-
vers, MA, USA) followed by an appropriate biotinylated sec-
ondary antibody. Brain sections were visualized using the ABC 
kit (Vector, Burlingame, CA, USA) and reacted with diamino-
benzidine substrate (DAB; Sigma-Aldrich). To determine the 
fluorescent immunohistochemistry, brain sections were im-
munostained with primary antibodies (AQP1 [AB9566; Abcam, 
Cambridge, UK], AQP4 [AB3068; Millipore, Bedford, MA, USA], 
AQP 9 [AB3091; Millipore]) and visualized using a fluorescence-
conjugated secondary antibody. Nuclei were counterstained 
with 4´ , 6-diamidino-2-phenylindole (DAPI). Sections were vi-
sualized using a fluorescence microscope (LSM 510 META; Carl 
Zeiss, Oberkochen, Germany).
Measurement of protein expression by immunoblotting
Brain tissues were dissected from the animals, homogenized, 
and lysed with ice-cold RIPA buffer and protein inhibitors (2 
µg/mL aprotinin, 5 µg/mL leupeptin, 1 µg/mL pepstatin A, 1 
mM phenylmethanesulfonyl fluoride [PMSF], 5 mM EDTA, 1 
mM EGTA, 5 mM NaF, 1 mM Na3VO4), and incubated on ice for 
60 min. Protein concentrations in the supernatants were deter-
mined using bicinchoninic acid (BCA) protein assay kits (Ther-
mo Scientific, Rockford, IL, USA), and equal amounts of protein 
were subjected to electrophoresis on 10%-12.5% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
gels. Separated proteins were electro-transferred to polyvinyli-
dene difluoride membranes (Millipore), and then the mem-
branes were blocked with 5% bovine serum albumin (BSA) in 
Tris-buffered saline (TBS). The membranes were incubated 
overnight with a specific primary antibody against ERK (#9102), 
p-ERK (#9101), JNK (#9252), p-JNK (#9255), p-P38 (#4631; all 
from Cell Signaling), NF-κB p-65 (AB1606; Millipore), or β-actin 
(AB8226; Abcam) as indicated. Immunoreactive bands were 
detected with horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies and visualized using the West Pico chemilu-
minescent substrate kit (Thermo Scientific). The band intensi-
ties were quantified using Image J software (Image J 1.36b; NIH, 
Rockville Pike, MD, USA).
Measurement of cytosolic/nuclear fractionized protein 
expression by immunoblotting
Brain tissues were dissected from the animals, homogenized, 
and lysed with ice-cold lysis buffer A (pH 7.9; 10 mM HEPES, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol [DTT], 0.05% 
NP40 and protein inhibitors [2 µg/mL aprotinin, 5 µg/mL leu-
peptin, 1 µg/mL pepstatin A, 1 mM PMSF, 5 mM EDTA, 1 mM 
EGTA, 5 mM NaF, 1 mM Na3VO4], and then were incubated on 
ice for 15 min. After incubation, the lysates were centrifuged at 
14,000 × g for 20 min at 4°C. Supernatants were collected for 
the cytosolic fractions, and pellets were resuspended in lysis 
buffer B (pH 7.9; 5 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 
0.5 mM DTT, 26% glycerol [v/v], 300 mM NaCl and protein in-
hibitors [2 µg/mL aprotinin, 5 µg/mL leupeptin, 1 µg/mL pep-
statin A, 1 mM PMSF, 5 mM EDTA, 1 mM EGTA, 5 mM NaF, 1 
mM Na3VO4]) and incubated on ice for 30 min. After incubation, 
the lysates were then centrifuged at 24,000 × g for 20 min at 4°C, 
and the supernatants were collected for the nuclear fractions. 
The protein concentrations in the lysates were determined us-
ing BCA protein assay kits (Thermo Scientific), and samples con-
taining equal amounts of protein (40 μg) were subjected to elec-
trophoresis on 10% SDS-PAGE gels. Separated proteins were 
then electro-transferred to Immobilon-NC membranes (Milli-
pore), and the membranes were next blocked with 5% BSA in 
TBS. The membranes were incubated overnight with a specific 
primary antibody against NF-κB p65 (AB1606), β-actin (AB8226), 
or histone H1 (sc-8030) as indicated. Immunoreactive bands 
were detected using HRP-conjugated secondary antibodies and 
visualized using the West Pico chemiluminescent substrate kit 
(Thermo Scientific). The band intensities were quantified using 
Image J software (Image J 1.36b; NIH, Rockville Pike, MD, USA).
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Statistical analysis
Data were presented as the mean ± standard error of the mean 
(SEM) of at least three different experiments, and duplicate or 
triplicate determinations were performed in each experiment. 
Statistical tests were performed with Student’s t-test using SAS 
ver. 8.01 (SAS Institute Inc., NC, USA). A P value less than 0.05 
was deemed to indicate statistical significance.
Ethics statement
All of the animal procedures were carried out according to a pro-
tocol approved by the institutional animal care and use commit-
tee (IACUC) of Yonsei University Animal Research Center 
(YLARC) using National Institutes of Health (NIH) guidelines. 
All of the animals were maintained in a specific pathogen-free 
facility of the YLARC (IACUC Approval No. 2011-0212 ). 
 
RESULTS 
Effect of agmatine on BBB disruption, brain edema, and 
apoptotic cell death after TBI
To determine whether agmatine treatment attenuates BBB dis-
ruption and brain edema after TBI, Evans Blue extravasation 
Fig. 2. Agmatine treatment significantly attenuated brain edema and neural cell death after TBI. Measurements were made of the Evans Blue extravasations (A), the Evans Blue 
stained area (mm2) (B), swelling volume (C), and brain water content (D). Hematoxylin and eosin (H & E) staining (E), relative necrotic area measurement (F), and TUNEL-positive 
cells in the ipsilateral cortex (G) were all significantly suppressed. Data are expressed as the mean±SEM (*P < 0.05 vs. EC). EC (n = 4), experimental control group; Agm (n = 4), 
agmatine treatment group. 
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and brain water content were analyzed. Agmatine treatment 
reduced the area of Evans Blue extravasation (39.27 mm2; 17.9 
%) 7 days after TBI (Fig. 2A and B), and the swelling volume was 
significantly decreased (5.24 mm2; 5.2%) 7 days after TBI (Fig. 
2C) compared with that of control animals. The brain water con-
tent was reduced in the agmatine treatment group at 1 and 2 
days after TBI (Fig. 2D). Agmatine treatment significantly re-
duced the necrosis area (3.56 ± 0.1% for 2 days, 2.46 ± 0.2% for 
7 days; Fig. 2E and F) and the number of TUNEL-positive cells 
at 2 and 7 days after TBI (Fig. 2G) compared with that of the con-
trol animals.
Effect of agmatine on neurological motor function after 
TBI
To investigate whether agmatine treatment reduces the deficits 
in motor functional behavior following TBI, rotarod and limb 
placing tests were performed. Compared with control animals, 
animals treated with agmatine showed a significant behavioral 
improvement from 1 to 7 days after TBI (Fig. 3A) as measured 
by the rotarod test. However, the results of limb placement test 
for the evaluation of motor coordination were not significantly 
different in agmatine-treated compared with control animals 
from 1 to 7 days after TBI (Fig. 3B).
Effect of agmatine on the expression of AQPs after TBI
To investigate whether agmatine attenuates brain edema for-
mation after TBI by regulating AQPs, the expression of AQP1, 4, 
and 9 was analyzed. We found that AQPs were significantly de-
creased in the agmatine treatment group 7 days after TBI using 
immunohistochemistry (Fig. 4A-C). In addition, the protein ex-
pression of AQPs was suppressed in the agmatine treatment 
group at 7 days after TBI as measured by immunoblotting (Fig. 
4D).
Effect of agmatine on the phosphorylation of MAPKs after 
TBI
To investigate whether agmatine regulates the phosphorylation 
of MAPK after TBI, the expression of MAPKs was analyzed by 
immunohistochemistry and immunoblotting. Agmatine treat-
ment suppressed the number of JNK- and P38 MAPK-positive 
cells at 1, 2, and 7 days after injury but activated the phosphory-
lation of ERK expression (Fig. 5A-C). By contrast, pJNK and pP38 
MAPK expression was significantly suppressed in the agmatine 
treatment group from 1 to 7 days after TBI (Fig. 5D-G). 
Effect of agmatine on nuclear translocation of NF-κB after 
TBI
To investigate whether agmatine regulates the nuclear translo-
cation of the NF-κB p65 subunit after TBI, the expression of NF-
κB p65 was analyzed by immunoblotting. Agmatine significant-
ly decreased the cytosolic expression of NF-κB p65 but increased 
the translocation of NF-κB p65 to the nucleus 1 day after TBI (Fig. 
6A-D).
DISCUSSION 
In the present study, we hypothesized that agmatine may have 
neuroprotective effects on apoptotic cell death and brain ede-
ma after TBI. Previous studies have suggested that agmatine 
treatment decreases the size of infarcts in a mouse ischemia 
model and promotes survival in neurons after oxygen-glucose 
deprivation (OGD) (18), reduces excitotoxicity in vitro by block-
ing NMDA receptor activation (15, 19), and protects neurons 
from injury (12) by the inhibition of nitric oxide synthase (18). 
The present study used TUNEL staining to determine agmatine 
treatment decreased TUNEL-positive cells 2 to 7 days after TBI. 
It is possible that cells undergoing necrotic cell death could also 
be improperly labeled by TUNEL staining, although this result 
Fig. 3. Agmatine ameliorated neurological behavior dysfunction after TBI. The rotarod test (A) and limb placement test (B) were conducted in control and experimental animals. 
Agmatine administration promoted motor function under both conditions. Data are expressed as the mean±SEM (*P < 0.05 vs. EC). 
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suggests that agmatine ameliorated neuronal cell death after 
TBI. In addition, recent studies have implicated the MAPK path-
way in the progression of acute brain damage after ischemia or 
trauma. The expression of MAPK proteins was activated by vari-
ous stress stimuli, including bacterial LPS and osmotic shock (6, 
8). Generally, ERK is centered on multiple signal transduction 
pathways to accomplish a variety of functions, including prolif-
eration, differentiation, and survival. Activation of JNK and p38 
kinase signaling pathways tends to promote apoptosis, whereas 
activation of ERK signaling pathway tends to be anti-apoptotic 
role in the nucleus (29, 30). In this study, agmatine treatment 
suppressed the phosphorylation of JNK and p38 kinase, where-
as activation of phosphorylated ERK after TBI. These results 
suggests that agmatine could regulates transcription of apopto-
sis and necrosis by MAPKs after TBI. The next question arises 
concerning how agmatine regulates transcriptional activation 
and apoptosis by suppressing MAPK phosphorylation after 
TBI. NF-κB translocation was investigated to analyze transcrip-
tional activation and anti-apoptotic gene regulation. Previously, 
NF-κB was shown to trigger several anti-apoptotic genes that 
interrupt the apoptotic cascade at multiple levels (10, 11) and 
to play a pivotal role in the regulation of cell survival and cell 
death. In addition, strong evidence supports that NF-κB func-
tions as an anti-apoptotic transcription factor in various cell 
populations, including neurons and astrocytes (10, 31, 32). Our 
results suggest that agmatine treatment has an anti-apoptotic 
effect by activating NF-κB nuclear translocation in TBI. Nuclear 
translocation of NF-κB should lead to suppress the apoptotic 
Fig. 4. Agmatine attenuated edema formation by suppressing AQPs after TBI. Agmatine attenuated aquaporin expression 7 days after TBI. Immunohistochemistry of AQP1, 4, 
and 9 (A-C) and the protein expression of AQP1, 4, and 9 (D) were analyzed. Data are expressed as the mean±SEM (*P < 0.05 vs. EC).
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Fig. 5. Agmatine suppressed JNK and P38 MAPK phosphorylation after TBI. Representative expression of phosphorylated ERK (A), JNK (B), and P38 MAPK (C) in control ani-
mals are shown in immunohistochemistry (A-C) and immune blotting (D). Agmatine suppressed the phosphorylation of JNK (F) and P38 MAPK (G) 1 day after TBI. However, ag-
matine treatment increased the phosphorylation of ERK (E) after TBI. Data are expressed as the mean±SEM (*P < 0.05 vs. EC).
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cell death after TBI. 
 Furthermore, accumulating evidence has shown that TBI 
could induce the breakdown of the BBB, a pathological hall-
mark of neurotrauma from in vivo and in vitro studies (33, 34). 
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Fig. 6. Agmatine promoted NF-κB p65 translocation into the nucleus after TBI. Protein expression of cytosolic NF-κB p65 (A) and nuclear NF-κB p65 (B) are shown. Agmatine 
caused significant translocation of NF-κB p65 into the nucleus 1 day after TBI. Optical density of cytosolic fraction (C) and nuclear fraction (D) were analyzed. Data are express-
ed as the mean±SEM (*P < 0.05 vs. EC).
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TBI is generally considered to the vasogenic origin of edema, 
sequential secondary injury promotes the opening of the BBB 
(35). Our previous study suggested that agmatine attenuated 
brain edema by limiting BBB disruption and blocking the accu-
mulation of brain water content by decreasing AQP1 expression 
after cerebral ischemia (22). In addition, AQP4 is primarily ex-
pressed in astrocytes at the BBB, where it plays a role in water 
transport between fluid compartments within the brain (36). 
AQP4-null mice are partially protected from brain edema caused 
by hyponatremia or ischemia (37). Thus, dysfunction of AQP4 
protects against cytotoxic (cellular) brain edema with intact BBB 
(38). AQP9 is also found on astrocyte processes and has specific 
permeability potential to lactate and water. AQP9 could contrib-
ute to lactic acidosis because it is permeable to water and lactic 
acid under pathological conditions (38, 39). Therefore, AQPs 
control water movement and are a potential therapeutic target 
for brain edema. Recent report suggested that MAPK pathways 
mediated cellular osmolarity by regulating aquaporin family. 
ERK activation is necessary for AQP5 induction by hyperosmot-
ic stress (8). Phosphorylated P38 MAPK is also a key regulator 
of AQP4 and AQP9 under hyperosmotic and ischemic condi-
tions in cultured cortical astrocytes (8, 9). Based on these ob-
servations, our results suggest that agmatine attenuated brain 
edema via AQPs through MAPK pathways under a pathological 
condition. In conclusion, we suggest that agmatine has neuro-
protective effects by attenuating necrosis, BBB disruption, and 
brain edema after TBI. These neuroprotective effects involve 
reducing the expression of phosphorylated MAPKs and AQP1, 
4, and 9 while promoting nuclear translocation of NF-κB after 
TBI. Therefore, agmatine treatment may have beneficial effects 
following various CNS injuries.
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